Takeda to Divest Four Diabetes Products in Japan to Teijin Pharma Limited
Takeda Provides Updates on Phase 1/2 Clinical Trials of Novavax’ and Moderna’s COVID-19 Vaccine Candidates in Japan
Takeda's Maribavir Phase 3 Clinical Trial Met Primary Endpoint of Superiority to Conventional Antiviral Therapy in Transplant Recipients With Refractory, With or Without Resistance, Cytomegalovirus Infection/Disease
Takeda Submits New Drug Application to Manufacture and Market Darvadstrocel In Japan for Treatment of Complex Perianal Fistulas in Adult Patients with Crohn’s Disease
Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS)
SEE ALL NEWS AND RELEASES >
・For Shire news releases, click here
Understanding the Role of Orexin in Sleep and Wakefulness
Exploring New Paths in Narcolepsy
Spotlight Malawi: Many Paths Towards Universal Health Coverage and a Strong Health Workforce
Guided by Our Values: Supporting Global COVID-19 Response
A ‘Swiss Cheese’ Approach Can Give Us a Second Chance to Contain COVID-19
SEE ALL FEATURED TOPICS ARTICLES >
With this new original series featured in Asahi Shimbun Globe, President & CEO Christophe Weber gives his unique perspective on what he has learned from his upbringing in France and his international career.
For media inquiries or reporter requests for more information, contact our Corporate Communications via Media_Relations@takeda.com. If you generally would like to contact us, please visit Contact Us.
Copyright 1995-2021 Takeda Pharmaceutical Company Limited. All rights reserved.